The company's Goa manufacturing facility has successfully completed prior approval inspection by the United States Food and Drug Administration (USFDA) without any observations, Lupin said in a statement.
The inspection which started on July 17 concluded today afternoon, it added.
Shares of Lupin Ltd today closed 1.99 per cent lower at Rs 1,142.85 per scrip on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content